|Free Dividend Report|
|Stock Splits Calendar|
|ACUR Stock Split History|
|Preferred Stock Newsletter|
|ACUR Options Chain|
|ACUR Message Board|
ACUR (ACUR) has 2 splits in our ACUR split history database. The first split for ACUR took place on August 27, 2015. This was a 1 for 5 reverse split, meaning for each 5 shares of ACUR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split. ACUR's second split took place on August 28, 2015. This was a 1 for 5 reverse split, meaning for each 5 shares of ACUR owned pre-split, the shareholder now owned 1 share. For example, a 200 share position pre-split, became a 40 share position following the split.
When a company such as ACUR conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ACUR split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ACUR shares, starting with a $10,000 purchase of ACUR, presented on a split-history-adjusted basis factoring in the complete ACUR split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-43.89%|
|Acura Pharmaceuticals is a pharmaceutical company engaged in the research, development and commercialization of technologies and products focusing on medication abuse and misuse. Co. has three proprietary platform technologies: Limitx technology focuses on abuse by excess oral consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets; Aversion Technology incorporates gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection; Oxaydo Tablets, Oxaydo (oxycodone HCI tablets) is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. According to our ACUR split history records, ACUR has had 2 splits.|
|ACUR Split History Table|
|08/27/2015||1 for 5|
|08/28/2015||1 for 5|
|Healthcare Stock Splits|
|ACUR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|